ALS is a disease that destroys the nerve cells in the brain and spinal cord we need for voluntary movement. There is no cure, but now there is a newly approved medication that may slow down the disease and extend patients' lives. The drug, called Relyvrio, got its start with a couple of college students, some "ice bucket challenge" money, and a new approach to targeting this disease. Neuroscience correspondent Jon Hamilton checks in with host Emily Kwong about why some advisors aren't persuaded the drug works and how you weigh promising but limited evidence against the backdrop of a 100% fatal disease with hardly any other treatment options?
To manage podcast ad preferences, review the links below:
See
pcm.adswizz.com for information about our collection and use of personal data for sponsorship and to manage your podcast sponsorship preferences.
Learn more about sponsor message choices:
podcastchoices.com/adchoicesNPR Privacy Policy